2023January17 Rise to Immunize Email edited for Rise to Immunize

Hello Colleagues,


2022 4th quarter LVHN results are now in for AMGA's **Rise to Immunize**<sup>m</sup> – a national campaign that aims to improve routine adult immunization rates and collectively administer 25 million vaccines by 2025. LVHN is one of over 60 medical groups and health systems participating in this campaign.

## Congrats to the attached high performing providers administering vaccines to our adults at LVHN!

## See attached document for the highest performers in each category.

This last quarter ending December 31, 2022 is different compared to prior quarters in that **pneumococcal vaccine for Rise to Immunize is reported as only those who have received any** *conjugate* **pneumococcal vaccine (PCV13, PCV15, PCV20).** The polysaccharide vaccine (PPSV23) is not counted in this measure. Part A covers those who received the vaccine during the measurement period (July 1, 2022 – Dec 31, 2022), while Part B covers those who received a conjugate vaccine prior to the measurement period. This change also affects the Bundle measurement which includes having had 4 adult vaccines: influenza, pneumococcal, Td/Tdap and zoster.

If we compare our pneumococcal vaccine rates to prior quarters, you can see that our rates have declined, even if we use the prior methodology of having received ANY pneumococcal vaccination. There is a decline from \_\_% in Q3 2020 to \_\_% in Q4 2022 reporting *any* pneumococcal vaccine, and a \_\_% rate in Q4 2022 when reporting only any *conjugate* vaccine. (*Percentages removed from graph*).




Looking at our rates on the dashboard, you can also see the difference in pneumococcal rates on our respective campuses. (These rates include polysaccharide vaccination rates).


(graph removed)

As of January 28, 2022, the CDC pneumococcal vaccine recommendations changed. Per MMWR, adults aged ≥65 years who have not previously received PCV or whose previous vaccination history is unknown should receive 1 dose of PCV (either PCV20 or PCV15). When PCV15 is used, it should be followed by a dose of PPSV23. The same is true for adults aged 19–64 years with certain underlying medical conditions or other risk factors. There is now a standing LVPG order for adults 65 and older and LVPG practices should be carrying PCV20. Please look at the Care Gaps and utilize your standing orders to reduce illness and death.

**Our flu vaccine rates continue below rates of 2019 and 2020.** We are in flu season. Please continue to encourage flu vaccines. Flu vaccines are safe and effective. Your strong recommendation for a flu vaccine makes a difference! (Percentages removed from graph below).



Congratulations to all of you! Our Td/Tdap and Zoster rates continue to rise! Last quarter we moved up 3 rankings in our Td/Tdap compared to other institutions. We will see if we are able to maintain our status at the end of 2022. Remember that these vaccines are now FREE TO ALL MEDICARE RECIPIENTS IF GIVEN IN A PHARMACY SETTING. Please recommend the vaccines and direct them to the nearest pharmacy. (Percentages removed from graphs below).



Look next month for comparison of our rates to other organizations involved in the Rise to Immunize campaign.